Daniel Von Hoff

Daniel Von Hoff is a legendary oncologist who led the MPACT trial establishing nab-paclitaxel plus gemcitabine as a first-line standard for pancreatic cancer. His decades of work in pancreatic oncology have spanned drug discovery, pharmacology, molecular tumor profiling, and clinical development. He pioneered individualized cancer therapy using drug sensitivity testing on patient tumor specimens. His contributions have fundamentally shaped how pancreatic cancer is treated worldwide.